VIRTUE study: effects of vildagliptin versus sulphonylureas as monotherapy or combined with metformin in Muslim patients with type 2 diabetes fasting during Ramadan

被引：0
|
作者：
Shaltout, I. [1 ]
Pathan, F. [2 ]
Medlej, R. [3 ]
Al-Arouj, M. [4 ]
Hassoun, A. A. K. [5 ]
Chawla, M. S. [6 ]
Knap, D. [7 ]
Vaz, J. A. [8 ]
机构：
[1] Cairo Univ, Cairo, Egypt
[2] BIRDEM Hosp, Dhaka, Bangladesh
[3] St Joseph Univ, Chron Care Ctr, Beirut, Lebanon
[4] Dasman Diabet Inst, Dasman, Kuwait
[5] Dubai Diabet Ctr, Dubai, U Arab Emirates
[6] Lina Diabet Care Ctr, Mumbai, Maharashtra, India
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
883
引用
收藏
页码：S359 / S359
页数：1
相关论文
共 50 条
  • [21] Vildagliptin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy: efficacy and tolerance at 52 weeks
    Halimi, S.
    Dejager, S.
    Arnou, R.
    Delamare, G.
    Ferrannini, E.
    [J]. DIABETES & METABOLISM, 2009, 35 : A8 - A8
  • [22] Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting
    Mafauzy, M
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2002, 58 (01) : 45 - 53
  • [23] Impact of fasting during Ramadan in patients with type 2 diabetes mellitus
    Haydardedeoglu, Filiz Eksi
    Bagir, Gulay Simsek
    Ozsahin, Akatli Kursat
    [J]. CUKUROVA MEDICAL JOURNAL, 2019, 44 (03): : 758 - 763
  • [24] Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes
    Nathwani, Ameet
    Lebeaut, Alexandre
    Byiers, Stuart
    Gimpelewicz, Claudio
    Chang, Ih
    [J]. DIABETES, 2006, 55 : A113 - A113
  • [25] Effects of vildagliptin combined with metformin on vascular endothelial function and systemic metabolism in patients with type 2 diabetes
    Takase, T.
    Kitao, N.
    Miyoshi, H.
    Furumoto, T.
    Ono, K.
    Nomoto, H.
    Miya, A.
    Yamamoto, C.
    Inoue, A.
    Tsuchida, K.
    Cho, K. Y.
    Nakamura, A.
    Kurihara, Y.
    Aoki, S.
    Atsumi, T.
    [J]. DIABETOLOGIA, 2017, 60 : S545 - S545
  • [26] Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes
    He, Yan-Ling
    Sabo, Ron
    Picard, Franck
    Wang, Yibin
    Herron, Jerry
    Ligueros-Saylan, Monica
    Dole, William P.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (05) : 1265 - 1272
  • [27] Cardiovascular safety of metformin and sulphonylureas in type 2 diabetes patients
    Ioacara, S.
    Roden, M.
    Guja, C.
    Ionescu-Tirgoviste, C.
    Reghina, A.
    Georgescu, O.
    Fica, S.
    [J]. DIABETOLOGIA, 2014, 57 : S318 - S318
  • [28] Lower risk of hypoglycaemia with repaglinide compared to glibenclamide during Ramadan fasting in Muslim patients with type 2 diabetes mellitus
    Mafauzy, M
    [J]. DIABETOLOGIA, 2001, 44 : A60 - A60
  • [29] IMPACT OF FASTING DURING RAMADAN ON CGM METRICS IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH METFORMIN, SULFONYLUREA AND/OR BASAL INSULIN
    Baghous, H.
    Meftah, A.
    Azzoug, S.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A234 - A234
  • [30] Does addition of vildagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?
    Retnakaran, Ravi
    [J]. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (08): : 572 - 573
12345